MZMarina Vladimirovna Zhuravleva

Marina Vladimirovna Zhuravleva

*This is an algorithmically generated author record based on publicly available information.

Marina Vladimirovna Zhuravleva has a total of 408 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prospects for integrating artificial intelligence into the practice of gastroenterologists and hepatologists

    by N. G. Bogdanova, S. Yu. Serebrova, V. I. Klimov, E. Yu. Esakova, M. V. Zhuravleva, Н. Г. Богданова, С. Ю. Сереброва, В. И. Климов, Е. Ю. Есакова, М. В. Журавлева

    Introduction. Artificial intelligence (AI) in clinical practice refers to a set of digital analysis methods capable of performing tasks that typically require a physician's involvement. Unlike conventional medical software, AI algorithms process vast amounts of historical health data to identify patterns and apply them to analyze new data. Sought-after technologies in this field include machine learning, neural network-based deep learning (DL), and large language models (LLMs). Aim. To evaluate the potential and limitations of AI technologies in gastroenterological practice and to explore their contribution to the optimization and enhancement of the quality of clinical decision-making. Materials and methods . A literature search of PubMed/MEDLINE, eLIBRARY.RU, and Google Scholar databases was conducted for the period from 2021 to August 2026. A total of 204 papers were evaluated, and 97 were included in the review. The search terms were as follows: artificial intelligence, machine learning, deep learning, neural networks, large language models, clinical practice, medical diagnostics, multi-criteria decision analysis, explainable artificial intelligence. A supplementary manual search of the reference lists of relevant reviews was conducted. Results. AI systems can analyze diagnostic images, predict disease outcomes, and computerize document processing. Algorithm training replicates clinical experience: the model can acquire differential diagnosis skills by analyzing endoscopic images. LLMs structure electronic health record (EHR) data and support differential diagnosis. MCDA takes into account patients’ quality of life, their individual characteristics, resource constraints, clinical priorities, and prognosis of the individual course of disease. At the same time, AI lacks clinical reasoning and causal reasoning capabilities; performance of AI models is determined by AI training data quality. Conclusion. AI technologies in healthcare serve as supportive tools for physicians that aid, rather than replace, the clinical reasoning of clinicians and other healthcare professionals. Mandatory validation of the scope and efficacy of AI solutions in accordance with established methodological and regulatory requirements will become a reliable basis for their integration into gastroenterologal practice and medical care standards.

  • Open Access

    Management of adult patients with musculoskeletal and neuropathic pain in primary care. Guidelines

    by O. M. Drapkina, O. N. Dzhioeva, N. V. Drogashevskaya, E. M. Zharova, M. V. Zhuravleva, M. L Kukushkin, A. V. Naumov, O. N. Tkacheva, R. N. Shepel, О. М. Драпкина, et al.

    These guidelines are intended for general practitioners (GPs) providing care to adult patients with acute and chronic musculoskeletal and/or neuropathic pain. The document presents a practical algorithm that integrates the assessment of urgency, identification of red flags, probable mechanism of the pain, selection of initial non-pharmacological and pharmacological therapy, monitoring of efficacy and safety, and criteria for referral to a specialist. The guidelines separately address the management of care at various levels, continuity of care, management of patients with multimorbidity, assessment of gastrointestinal and cardiovascular risks prior to prescribing non-steroidal anti-inflammatory drugs, management of neuropathic pain, prescription requirements, and subsidized pharmaceutical provision. The importance of aligning treatment goals with the patient and evaluating not only changes in pain intensity but also the restoration of sleep, activity, and daily functioning is emphasized. These guidelines supplement, but do not replace, clinical guidelines for specific diseases and should be applied taking into account contraindications, comorbidities, drug interactions, and regional patient routing protocols.

  • Кинетика высвобождения диклофенака из кишечнорастворимых таблеток разных производителей и ее клинико-фармакологическая интерпретация

    by Светлана Юрьевна Сереброва, Ангелина Викторовна Колячкина, Людмила Михайловна Красных, Елена Юрьевна Есакова, Руслан Евгеньевич Казаков, Марина Владимировна Журавлева, Елена Ивановна Городецкая, Елена Николаевна Карева, Наталья Николаевна Еременко, Алексей Борисович Прокофьев

    Безусловную актуальность приобретают исследования, целью которых является изучение взаимозаменяемости лекарственных средств, присутствующих на фармацевтическом рынке Российской Федерации. Одним из методов оценки качества твердых дозированных лекарственных форм препаратов является тест сравнительной кинетики растворения (ТСКР), который позволяет изучить и сравнить скорости и степени высвобождения in vitro активного компонента. С помощью ТСКР изучено высвобождение оригинального и двух воспроизведенных препаратов диклофенака разных производителей. Методом высокоэффективной жидкостной хроматографии (ВЭЖХ) определяли концентрацию диклофенака в аликвотах, отобранных через 5, 10, 15, 20, 30, 45 и 60 мин в растворе с pH 6,8 ± 0,05, после 2 ч экспозиции при pH 1,2 ± 0,05 или 4,5 ± 0,05. Оценивали также концентрации диклофенака в среде растворения с pH 4,5 ± 0,05. Временная точка 10 мин — время воздействия патологического дуоденогастрального рефлюкса на лекарственную форму диклофенака. Показано, что изученные препараты не могут быть в полной мере признаны эквивалентными оригинальному препарату в изучаемых условиях in vitro.

  • Open Access

    Protocol for preparation, transplantation, rehabilitation, and follow-up of patients with upper limb loss

    by N. E. Manturova, A. S. Tokarev, S. S. Petrikov, V. I. Sharobaro, M. G. Minina, M. Sh. Khubutiya, A. G. Balkarov, D. V. Lonshakov, P. A. Drozdov, M. V. Zhuravleva, et al.

    Background. The introduction of upper limb allotransplantation in Russia required the development and implementation of a systematic, multidisciplinary approach to these operations. Objective. To develop a protocol for the preparation, transplantation, rehabilitation, and follow-up of patients with upper limb loss. Material and methods. A literature review was conducted covering all theoretical and practical aspects of upper limb allotransplantation using the PubMed, Springer, Scopus, and Web of Science databases from 1998 to 2026, and the long-term outcome of the first successful upper limb allotransplantation in Russia, performed on April 20, 2025 at the N.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow City Health Department, was taken into account. Results. A detailed protocol was developed covering the preparation and selection of patients, the allotransplantation procedure, the postoperative period, rehabilitation, and follow-up of patients with upper limb loss. Conclusion. The presented protocol confirmed its effectiveness through the success of the first upper limb allotransplantation in Russia and is therefore recommended for practical use.

  • Open Access

    Safety of Psychopharmacotherapy in Patients With a Psychosomatic Profile: A Retrospective Study Using the Global Trigger Tool

    by A. A. Anderzhanova, Yu. A. Meleshkina, M. V. Zhuravleva, S. V. Yakovlev, M. V. Lukina, M. A. Balalaeva, А. А. Андержанова, Ю. А. Мелешкина, М. В. Журавлева, С. В. Яковлев, et al.

    INTRODUCTION. Combined psychopharmacotherapy in patients with comorbid psychiatric and somatic disorders creates a high risk of adverse drug reactions (ADRs). The Global Trigger Tool (GTT) enables active screening and quantitative assessment of ADRs developing under the influence of various factors in routine clinical practice and helps identify directions for optimizing therapeutic strategy. AIM. To evaluate the frequency and structure of ADRs during psychopharmacotherapy in patients with a psychosomatic profile and to identify associations between the use of specific drugs, combined psychopharmacotherapy, and the development of ADRs using the Global Trigger Tool. MATERIALS AND METHODS. A single-center retrospective study was conducted that included 491 medical records of patients hospitalized in a psychosomatic department from January 2024 to March 2025. A list of 27 triggers, adapted for patients receiving psychopharmacotherapy, was used to identify ADRs. Statistical analysis was performed using Fisher exact test. RESULTS. Twenty-five types of ADRs were identified. The most frequently recorded were cardiovascular disorders ( n =211), anticholinergic effects ( n =113), and hematological reactions ( n =89). Concomitant use of 2 or more psychotropic drugs was associated with an increase in the incidence of extrapyramidal symptoms (up to 14.1%, p p p p =0.005); arterial hypotension with valproic acid ( p =0.044); and cardiotoxicity of pramipexole ( p =0.006) and levodopa ( p =0.012). CONCLUSIONS. The GTT is an effective method for retrospective safety audit of psychopharmacotherapy. Combined psychopharmacotherapy is an independent modifiable risk factor. New associations between specific drugs and ADRs were identified that require confirmation and validation in prospective studies.

  • Risk factors for bleeding in elderly patients with polypharmacy and chronic kidney disease on direct oral anticoagulants: integrating molecular mechanisms and pharmacogenetics

    by A. P. Kondrakhin, E. G. Silina, M. L. Maksimov, M. V. Zhuravleva, T. R. Kameneva

    Introduction. Modern advances in medicine have significantly increased life expectancy, but the molecular mechanisms of aging remain a complex and multifaceted problem. Telomere shortening, DNA damage, and mitochondrial dysfunction lead to a decrease in the functional reserves of organs and systems. Aging is not a linear process of degradation but rather a network of interrelated pathological cascades initiated by primary damages at the level of telomeres and mitochondria. This leads to systemic restructuring of molecular homeostasis and requires a revision of classical pharmacokinetic models for geriatric patients. Objective. To assess factors that increase the risk of bleeding when taking direct oral anticoagulants (DOACs) in elderly and senile patients with polypharmacy and chronic kidney disease, considering the molecular mechanisms of action of the drugs and individual pharmacogenetic characteristics. Materials and methods. The database included 503 patients observed at the Hospital for War Veterans No. 2 of the Moscow Healthcare Department from April to September 2023. Data were collected from anamnesis, surveys, and medical records. Clinical and laboratory parameters, biomarkers of renal function, coagulograms, as well as CYP3A4 and CYP2C19 activity were analyzed. Results. The use of DOACs increased the risk of bleeding with a decrease in creatinine clearance, especially when using dabigatran. Apixaban and rivaroxaban did not demonstrate a significant increase in bleeding in renal failure. Simultaneous use of DOACs and heparins significantly increased the risk of bleeding during the year of therapy. The concomitant use of dabigatran and verapamil also increased the risk of bleeding. Conclusion. To improve the safety of anticoagulant therapy in elderly patients, a personalized approach is needed, taking into account pharmacogenetic characteristics and molecular biomarkers. The study of drug interactions and their connection with clinical outcomes in large samples will identify predictors of adverse outcomes and optimize therapy.

  • Resolution of the Expert Council on the Rational Management of Patients with Diabetic Sensorimotor Polyneuropathy and Neuropathic Pain

    by G.R. Galstyan, O.M. Drapkina, O.N. Dzhioeva, I.V. Gurieva, P.R. Kamchatnov, M.L. Kukushkin, I.A. Strokov, V.N. Khramilin, S.K. Zyryanov, M.V. Zhuravleva, et al.

    Diabetic distal symmetric sensorimotor polyneuropathy (DPN) represents one of the most prevalent and clinically significant complications associated with diabetes mellitus (DM). The painful variant of this condition substantially diminishes the quality of life for affected individuals, is associated with sleep disorders, anxiety, and depression, and encompasses an increased risk of adverse outcomes. In real-world practice, reliance solely on screening questionnaires without neurological examinations can lead to the underdiagnosis of DPN, especially in its painless form, and the overdiagnosis of neuropathic pain. Objective. To articulate a consensus expert position regarding the rational diagnosis, routing, and treatment of patients with distal polyneuropathy and neuropathic pain across various levels of medical care. Materials and methods. The expert council conducted a thorough analysis of contemporary clinical guidelines, international consensus documents, the scientific literature, and the practical challenges associated with managing patients with diabetic polyneuropathy in both primary and specialized medical care settings. Results. The council identified key levels of patient referral, including primary health care, consultation with a neurologist and/or endocrinologist, and access to specialized pain management centers. A practice-oriented diagnostic algorithm for primary care is proposed that encompasses a targeted collection of patient complaints, assessment of symptomatology, evaluation of tactile, vibration, and pain sensitivity, and assessment of tendon reflexes. Clear indications for specialist referral, criteria for initiating therapy, treatment objectives for the painful variant of DPN, and strategies for assessing treatment effectiveness have been established. The successful implementation of these recommended approaches requires the development of a regulatory framework for patient routing, the introduction of concise clinical algorithms, the initiation of educational programs for primary care physicians, and the assurance of the availability of pharmacological therapy. Conclusions. Enhancing the quality of care for patients with distal polyneuropathy can be achieved through a strategic combination of organizational, educational, clinical, and methodological initiatives that facilitate early diagnosis and appropriate treatment.


  • Open Access

    Impact of psychopharmacotherapy on systemic inflammatory response markers in psychosomatic patients: A retrospective study

    by A. A. Anderzhanova, V. A. Mazus, M. V. Zhuravleva, S. Yu. Serebrova, S. V. Yakovlev, Yu. A. Meleshkina, M. V. Lukina, M. A. Balalaeva, А. А. Андержанова, В. А. Мазус, et al.

    INTRODUCTION. The safety of pharmacotherapy in patients with mental disorders is critical for accurate assessment of systemic inflammatory processes. Psychopharmacotherapy may modulate the immune response, potentially masking systemic inflammatory response (SIR) signs in patients with psychosomatic profile. This phenomenon complicates the differential diagnostic process and the selection of an appropriate treatment strategy. AIM. To evaluate the effect of pre-admission psychotropic medication use on key markers of systemic inflammatory response (body temperature, leukocytosis, and C-reactive protein (CRP) levels) to enhance the safety of psychotropic pharmacotherapy and optimize therapeutic strategies in hospitalized patients with mental disorders. MATERIALS AND METHODS. This single-center retrospective study analyzed data from 850 patients hospitalized between January 2024 and March 2025 with suspected infectious complications or decompensation of somatic pathology. Five classes of psychopharmacotherapeutic agents were evaluated: antipsychotics ( n= 270), antidepressants ( n= 56), antiepileptics ( n= 94), anxiolytics ( n= 15), and antiparkinsonian agents ( n= 63). Associations with febrile response (38 °C), leukocytosis, and elevated CRP levels were assessed using the Pearson χ² test, Fisher's exact test, and the linear-by-linear association test. RESULTS. No single drug class affected all three markers of SIR simultaneously. Antidepressant use was associated with a significant linear trend toward reduced fever severity ( p= 0.024). Antiepileptic use was associated with a lower incidence of leukocytosis ( p= 0.039). Polytherapy (use of ≥3 medications) was significantly associated with a decrease in leukocyte counts ( p= 0.008) and an increase in CRP levels ( p= 0.006). Among individual agents, chlorprothixene and chlorpromazine were associated with higher, while risperidone was associated with lower, SIR parameter values. CRP levels during inflammation remained consistently elevated and were not influenced by psychotropic medication use. CONCLUSIONS. Routine psychopharmacotherapy is not a universal confounding factor that distorts the picture of systemic inflammation. The effects are selective and most pronounced in the context of polytherapy. CRP, as the most stable marker, can serve as an objective indicator of inflammation, and data on the effects of individual antipsychotics on SIR markers can be used to optimize therapeutic strategies in patients with comorbid mental and somatic disorders.

  • Open Access

    Current potential for Helicobacter pylori triple pharmacotherapy

    by S. Yu. Serebrova, E. Yu. Esakova, N. B. Lazareva, G. I. Gorodetskaya, O. V. Dobrovolsky, M. V. Zhuravleva, A. B. Prokofiev, С. Ю. Сереброва, Е. Ю. Есакова, Н. Б. Лазарева, et al.

    Helicobacter pylori infection represents a global public health problem, as the pathogen is associated with the development of gastric and duodenal ulcer disease, gastritis, gastric adenocarcinoma, and MALT lymphoma. The efficacy of eradication therapy is declining due to increasing antibiotic resistance, necessitating a revision of therapeutic strategies. The article presents the mechanisms of H. pylori survival in the aggressive gastric environment, its pathogenicity factors, current data on the mechanisms of action of the main antibacterial drugs used for treating the infection in Russia and worldwide: clarithromycin, metronidazole, amoxicillin, tetracycline, levofloxacin, rifabutin, bismuth tripotassium dicitrate, as well as the mechanisms of resistance development for these agents. Single-phase and two-phase eradication therapy regimens are examined in detail according to the 2022 Russian clinical guidelines and the Maastricht VI consensus, including first-line regimens: standard triple therapy, bismuth-enhanced and non-bismuth-enhanced, concomitant, sequential, hybrid, reverse hybrid, bismuth-based quadruple therapy, high-dose dual therapy, and vonoprazan-based dual therapy. For second-line therapy, regimens including levofloxacin and rifabutin are reviewed, and the principles of individualized therapy are outlined. A brief clinical and pharmacological characterization of each drug is provided. The reasons for failures in finding the optimal H. pylori eradication regimen are also analyzed. The World Health Organization's changing stance toward H. pylori as a pathogen requiring the development of new antibacterial drugs is mentioned. The concepts of the "post-antibiotic era" and the renaissance of antibiotics are discussed. The concluding section examines the risks associated with the choice of first-line therapy regimens and the drugs included in them. It is concluded that with proper assessment of H. pylori resistance, triple pharmacotherapy with or without bismuth is a relatively effective and safe eradication regimen for regions of the Russian Federation. Consideration of clarithromycin metabolism characteristics and adverse drug reactions allows for rational selection of first-line therapy that accounts for the physiological and clinical features of patients with H. pylori infection.

  • Therapeutic and Prophylactic Bacteriophage Preparations: Efficacy, Safety, and International Regulatory Experience (Review)

    by R. E. Kazakov, S. Yu. Serebrova, E. Yu. Esakova, M. V. Zhuravleva, A. B. Prokofiev

    INTRODUCTION. Bacteriophage preparations are effective in bacterial infections, including multi-drug resistant pathogens. In order to develop and widely use standardized and personalized phage therapy, current regulations and guidelines governing the development, clinical trials, registration, and distribution of bacteriophage preparations necessitate an update. AIM. This study aimed to analyze global trends in the development, registration, as well as efficacy and safety assessment of bacteriophage preparations to identify promising areas for development of phage therapy in the Russian Federation. DISCUSSION. Despite the proven efficacy, rapidly expanding resistance of pathogens, complicated delivery to the infection focal point, and poorly understood safety of phage therapy prevent wide implementation of bacteriophages in clinical practice. In case standardized bacteriophage preparations show decreased effectiveness, a modified formulation may be warranted, with the updated strains; however, no appropriate legislative mechanisms exist so far. To date, 14 standardized bacteriophage preparations were registered and used in the Russian Federation, with completed clinical trials. Personalized phage therapy is used to a lesser extent. In the United States and the European Union (EU) member states, strict requirements for safety and efficacy evidence are placed; phage therapy is not an official treatment method but is used in individual cases. In some countries, particularly Poland and Belgium, phage therapy is under close supervision, while the use of bacteriophages remains individualized. In 2025, a draft of a concept document stipulating development and production of bacteriophage agents for human use was developed in the EU. However, none of the drugs for phage therapy was approved according to the EU and US requirements. CONCLUSIONS. Russian Federation has a unique experience of using standardized phage preparations. Regulatory algorithms of modifying the formulation of a registered bacteriophage preparation are still to be developed both in the Russian Federation and other countries. Worldwide harmonization of the regulatory base is an essential element of global development; points to consider include new EU and US initiatives on developing regulatory documents, intensified research aimed at overcoming bacterial resistance to bacteriophages, and long-term safety studies.